Kenting Bio's AK112 Data Supports Pipeline; Tetrabody Platform Demonstrates Expansion Potential

Overview

This report synthesizes management’s key insights from a Morgan Stanley webcast, focusing on the clinical data advancement of AK112 (ivonescimab), the value proposition of the Tetrabody platform technology, and the company’s strategy to expand its pipeline into ADC, autoimmune, and central nervous system (CNS) therapeutic areas. The report concludes that the positive H6 OS data for AK112 provides strong support for its ongoing H3 trial. The platform technology has demonstrated validation, and the company’s collaboration strategy prioritizes co-development with multinational corporations (MNCs) to enable global commercialization.

Core views

Management emphasized that AK112’s H6 OS HR of 0.66 signifies a statistically significant 34% reduction in risk of death, with manageable safety—findings consistent across four Phase III/HARMONi datasets and real-world data from over 70,000 Chinese patients. These results strongly support the ongoing H3 trial. No clear timeline has been provided for H2 OS updates, pending event maturity. Kenting Bio’s pipeline is anchored by its commercialized product AK104 (PD-1/CTLA-4) and Phase III-stage asset AK112 (PD-1/VEGF), and is expanding into ADC (AK146D1, targeting TROP2/Nectin-4, Phase II), autoimmune diseases (AK139, targeting IL-4Rα/ST2, Phase II), and CNS (AK152, anti-Aβ/TfR, Phase I). AK152 is positioned for best-in-class (BIC) potential: its BBB shuttle design reduces brain exposure and ARIA risk, and its selective targeting of Aβ oligomers follows Roche’s trontinemab. The Tetrabody platform has been validated twice through 'first-in-class' assets AK104 (used by over 100,000 Chinese patients) and AK112. Its tetravalent structure and high-affinity features preserve efficacy while mitigating the CTLA-4/VEGF-related toxicities of first-generation bispecific antibodies, and the platform’s versatility extends into ADC, autoimmune, and CNS therapeutic areas. In terms of collaboration, Kenting prefers co-development with MNCs rather than outright licensing, leveraging partners’ global commercial capabilities while integrating its own R&D expertise, China patient enrollment strength, and ability to execute global trials. Management expects regulatory paths will ultimately support cross-border collaborative development.

Analysis framework

The report distills management commentary from the webcast using two analytical pillars: clinical data interpretation and platform technology evaluation. It argues that AK112’s H6 OS data (HR 0.66) and safety profile robustly support the H3 trial design. It further validates Tetrabody’s expansion potential using AK104’s commercial scale and AK112’s rational design. Pipeline potential is assessed across ADC, autoimmune, and CNS sectors, while AK152’s differentiation versus competitors (e.g., Roche’s trontinemab) is analyzed. Collaboration strategy highlights economic upside retention and complementary execution capabilities to evaluate co-development feasibility.

Methodology notes

• Valuation MethodologyDCF (Discounted Cash Flow)

  Valuation performed using a discounted cash flow (DCF) model

  The report applies a DCF framework to assess Kenting Bio’s value, assuming a WACC of 8.9% (consistent with other biotech peers) and a terminal growth rate of 3%, appropriate for biotech companies with marketed products.

• Industry/sector analysis frameworkUpstream–midstream–downstream chain analysis

  Biotech platform value chain analysis

  The report traces value generation across the biotech value chain—上游 (platform technology), midstream (pipeline assets), downstream (commercialization)—highlighting the Tetrabody platform’s scalability as the primary value driver.

• Competition & strategy frameworkMoat / competitive advantage

  Moat analysis based on platform technology

  The report posits that Tetrabody’s high-affinity design and safety enhancements constitute a technology-driven moat, enabling competitive differentiation across multiple therapeutic areas.

• Industry/sector analysis frameworkSubstitution analysis

  AK152’s substitution potential versus конкурентов

  The report analyzes AK152’s BBB shuttle and Aβ selectivity to evaluate its differential substitution potential against Roche’s trontinemab.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Kenting Bio (9926.HK)

  Core investment thesis: AK112 data supports pipeline; Tetrabody platform validation

  Strengths

  Tetrabody platform demonstrates scalability; AK112 shows compelling clinical data; diversified pipeline布局

  Weaknesses

  No timeline for H2 OS reads; competitive landscape evolution poses risks

  Comparison

  AK152 follows trontinemab but offers BBB shuttle differentiation

  Risks

  R&D failure; competitive acceleration; partner collaboration delays

Key data

• AK112 H6 OS HR0.6634% reduction in risk of death; safety remains manageable
• AK104 Patients in China>100,000Commercial validation of platform technology
• AK112 Real-World Patients>70,000Data consistency supports H3 trial design
• Valuation WACC8.9%Input for baseline DCF model
• Terminal Growth Rate3%DCF assumption

Impact & implications

Positive AK112 data is expected to accelerate the H3 trial and enhance global commercial potential. Tetrabody validation bolsters long-term competitiveness and supports pipeline expansion into ADC, autoimmune, and CNS areas. If executed successfully, the co-development strategy could unlock global value while optimizing economic upside. AK152’s BIC potential may establish a new growth trajectory in CNS, though competitive pressure from Roche’s assets remains a key concern.

Risks

• Rapid launch of competing products leading to market share loss
• Evolving global competitive dynamics
• Pipeline delays or clinical failures

What to watch

• H3 trial data updates for AK112
• Timeline for H2 OS readout
• Progress on MNC partnership announcements
• Phase I data for AK152
• Advancement of AK146D1 and AK139 in Phase II